Resources from the same session
4O - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes
Presenter: Natalia Isabel Valdiviezo Lama
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Invited discussant 4O
Presenter: Joop De Langen
Session: Proffered Paper session
Resources:
Slides
Webcast
108O - Surgical outcomes from RATIONALE-315: Randomized, double-blind, phase III study of perioperative tislelizumab with neoadjuvant chemotherapy in resectable NSCLC
Presenter: Dongsheng Yue
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Invited Discussant 108O
Presenter: Jonathan Spicer
Session: Proffered Paper session
Resources:
Slides
Webcast
Q&A
Session: Proffered Paper session
Resources:
Webcast
LBA1 - Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2
Presenter: Jeffrey Bradley
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
193O - Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: A brief report from the CONVERT trial
Presenter: Gerard Walls
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Invited Discussant 193MO and LBA1
Presenter: Fiona McDonald
Session: Proffered Paper session
Resources:
Slides
Webcast
Q&A
Session: Proffered Paper session
Resources:
Webcast